{"id":90618,"date":"2026-05-23T16:13:27","date_gmt":"2026-05-23T16:13:27","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/90618\/"},"modified":"2026-05-23T16:13:27","modified_gmt":"2026-05-23T16:13:27","slug":"european-medicines-regulator-recommends-approval-for-novos-wegovy-pill-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/90618\/","title":{"rendered":"European medicines regulator recommends approval for Novo&#8217;s Wegovy pill"},"content":{"rendered":"<p class=\"mb-4 text-lg md:leading-8 break-words\">May 22 (Reuters) &#8211; The European Medicines Agency recommended approval \u200cfor Novo Nordisk&#8217;s weight-loss pill \u200cWegovy, the regulator said on Friday, \u200bclearing its path to become the first oral weight-loss drug in Europe, ahead of \u200cU.S. rival \u2060Eli Lilly.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">The recommendation comes as competition between Novo \u2060and Lilly intensifies, with both companies seeking to grow their \u200bshare of \u200bthe \u200bbooming obesity drug \u200cmarket\u2014expected by analysts to reach $150 billion annually in the next decade\u2014by expanding into oral treatments.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">Novo launched the pill in the \u200cUnited States earlier \u200bthis year after \u200bwinning \u200bFDA approval, giving it \u200can early start. \u200bLilly&#8217;s weight-loss \u200bpill, Foundayo, was launched in April following its U.S. \u200bapproval.<\/p>\n<p class=\"mb-4 text-lg md:leading-8 break-words\">(Reporting \u200cby Kunal Das and Puyaan \u200bSingh in Bengaluru; Editing \u200bby Tasim Zahid)<\/p>\n","protected":false},"excerpt":{"rendered":"May 22 (Reuters) &#8211; The European Medicines Agency recommended approval \u200cfor Novo Nordisk&#8217;s weight-loss pill \u200cWegovy, the regulator&hellip;\n","protected":false},"author":2,"featured_media":90619,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[276,32071,7734,272,18580,3388],"class_list":["post-90618","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly","tag-european-medicines-agency","tag-fda-approval","tag-novo-nordisk","tag-oral-treatments","tag-weight-loss-drug"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116624779233394551","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/90618","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=90618"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/90618\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/90619"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=90618"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=90618"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=90618"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}